OpenEvidence, a leading AI-powered medical search platform, announced a $210 million Series B funding round on July 15, 2025, valuing the company at $3.5 billion. Co-led by Google Ventures and Kleiner Perkins, with Sequoia Capital, Coatue, Conviction, and Thrive participating, the round brings OpenEvidence’s total funding to over $300 million. The company also launched OpenEvidence DeepConsult™, the first AI agent designed specifically for physicians, offering advanced research capabilities to support clinical decisions.
Funding: $210M Series B at $3.5B valuation, led by Google Ventures, Kleiner Perkins.
User Base: Used by 40% of U.S. physicians, with 65,000 new registrations monthly.
DeepConsult™: AI agent for in-depth medical research, free for verified U.S. clinicians.
Growth: Supports 8.5M+ clinical consultations monthly, up 2,000% year-over-year.
Partnerships: Integrates content from AMA, NEJM, and JAMA journals.
Impact: Reduces research time, combats physician burnout, improves patient outcomes.
OpenEvidence addresses the challenge of medical information overload, with research doubling every five years. “Physicians are drowning in information but starving for timely insights,” said Sangeen Zeb, General Partner at Google Ventures. The platform, used by over 430,000 U.S. physicians across 10,000+ medical centers, delivers real-time, evidence-based answers from peer-reviewed sources like the New England Journal of Medicine and JAMA, reducing research time from hours to seconds.
The newly launched DeepConsult™ empowers physicians with PhD-level AI agents that autonomously analyze hundreds of peer-reviewed studies, delivering comprehensive research reports. Unlike the core search tool, which provides answers in 5–10 seconds, DeepConsult tackles complex queries, producing interdisciplinary syntheses that would take human researchers months. Offered free to verified U.S. clinicians, it addresses a projected 100,000-physician shortfall by 2030.
With 8.5 million monthly clinical consultations and a 2,000% year-over-year growth rate, OpenEvidence is the fastest-adopted medical technology since the iPhone, used by 40% of U.S. physicians daily. “It’s the free-for-physician model that’s the magic here,” said John Doerr, Kleiner Perkins Chairman. The platform’s HIPAA-compliant, ad-supported model ensures accessibility while maintaining trust, with 75% of users leveraging it during office hours for patient care plans.
The funding will expand partnerships with leading medical journals, including the AMA and NEJM, enhancing OpenEvidence’s knowledge base. “The partnership between the American Medical Association and OpenEvidence represents a significant step toward fulfilling that promise,” said Robert M. Wachter, MD, Chair of UCSF’s Department of Medicine. Founded by Daniel Nadler, whose previous AI venture, Kensho, sold for $700 million, OpenEvidence is poised to redefine clinical decision-making globally.
OpenEvidence’s $210 million raise and DeepConsult™ launch mark a pivotal moment in healthcare AI, empowering physicians to deliver better care amidst growing demands and information complexity.
OpenEvidence is the fastest-growing clinical decision support platform in the United States, and the most widely used medical search engine among U.S. clinicians. Trusted by hundreds of thousands of verified physicians, nurses, and other healthcare professionals, OpenEvidence is actively used across more than 10,000 hospitals and medical centers nationwide and by over 40% of physicians in the United States who log in daily to make high-stakes clinical decisions at the point of care.
OpenEvidence continues to grow by over 65,000 new verified U.S. clinician registrations each month. Aside from Google itself, there has never been a piece of technology adopted by clinicians as quickly as OpenEvidence. OpenEvidence is transforming how frontline healthcare providers access, evaluate, and apply the world's medical knowledge. More than 100 million Americans this year will be treated by a doctor who used OpenEvidence.
OpenEvidence was founded by Daniel Nadler and Zachary Ziegler. Founded with the mission to organize and expand global medical knowledge, OpenEvidence is redefining evidence-based medicine in real-time. In recognition of this impact, in 2025, OpenEvidence founder Daniel Nadler, PhD, was named to the TIME100 Health list of the 100 Most Influential People in global health.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.